Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | SQOR | Q9Y6N5 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330855 | 0.81 | KDM4E (0.41) | SQORKDM4ELMNAMAPTCYP2C9 | |
| SCHEMBL1629238 | 0.81 | TRPV4 (0.39) | TRPV4SQORKDM4ELMNAMAPT | |
| SCHEMBL25564462 | 0.81 | CYP3A4 (0.45) | TRPV4KDM4ELMNAMAPTCYP2C9 | |
| SCHEMBL25330482 | 0.81 | SQOR (0.38) | SQORKDM4ELMNAMAPTCYP2C9 | |
| SCHEMBL31362476 | 0.80 | MAOB (0.31) | LMNAMAPK1 | |
| SCHEMBL22802480 | 0.78 | CACNA1H (0.39) | TRPV4SQORKDM4ELMNAMAPT | |
| SCHEMBL12763938 | 0.78 | PTGS2 (0.48) | TRPV4SQORKDM4EUSP2ALDH1A1 | |
| SCHEMBL12725005 | 0.78 | CACNA1H (0.41) | TRPV4SQORKDM4ELMNAMAPT | |
| SCHEMBL30753873 | 0.78 | G6PC1 (0.40) | TRPV4SQORKDM4ELMNATDP1 | |
| SCHEMBL185766 | 0.78 | TRPV4 (0.64) | TRPV4KDM4EDHODHALDH1A1EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016201219-A1 | SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| WO-2016201219-A1 | SMALL MOLECULE INHIBITORS OF DIHYDROFOLATE REDUCTASE | CIDARA THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| EP-2401270-B1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-8507543-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2013-08-13 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-20130030031-A1 | Novel Compounds | GLAXO GROUP LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2012025473-A1 | CC.CHEMOKINE RECEPTOR 4 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | WO | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| EP-2401270-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097395-A1 | PYRAZOLE DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | WO | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
| US-20100216860-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015932-A1 | Pyrazole Derivatives Used as CCR4 Receptor Antagonists | CCR4, CCR3, CCR1 | TRPV4 35/4885SQOR 3805/4885KDM4E 2789/4885 |
| US-20130030031-A1 | Novel Compounds | CYP3A4, CYP3A43, ABCG2 | TRPV4 2312/4885SQOR 160/4885KDM4E 3276/4885 |
| US-20100216860-A1 | NOVEL COMPOUNDS | CYP3A4, CYP3A43, ABCG2 | TRPV4 2312/4885SQOR 160/4885KDM4E 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.